"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial to see if other drugs affect the way bortezomib works in people with non Hodgkin lymphoma and myeloma
This trial is looking at whether other drugs affect the way the body breaks down bortezomib (Velcade) in people with non Hodgkin lymphoma or myeloma that has continued to grow.
More about this trial
Bortezomib is a type of biological therapy called a proteasome inhibitor. Doctors use it to treat myeloma that has come back after treatment. Clinical trials are currently looking at using bortezomib for people with non Hodgkin lymphoma.
This trial is looking at the effect of two drugs on bortezomib. The first is rifampicin. Rifampicin is not used to treat cancer. It is an antibiotic used to treat or prevent infections. The second is a steroid called dexamethasone. These two drugs activate an
The CYP3A4 enzyme breaks down bortezomib. Doctors think that rifampicin and dexamethasone will lower the amount of bortezomib because they increase the amount of the CYP3A4 enzyme. This may affect the way that bortezomib works. But researchers are not sure yet.
The results of this study may help doctors to improve treatment for people with myeloma and non Hodgkin lymphoma in the future.
Summary of results
Despite attempting to contact the trial team, we have been unable to check the results of this trial.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Simon Rule
Johnson and Johnson Pharmaceutical R+D